Pulmonary hypertension has been considered incurable in the recent past, and many physicians still hold this view. Little did we know that in recent years there have been dramatic developments in the field. New drugs and new ideas have emerged and have benefited many patients. It should be kept in mind that before choosing a drug treatment, it is important to first determine the diagnosis. In certain diseases, such as severe left heart disease and pulmonary disease, inappropriate treatment may lead to a worsening of the condition. In patients with severe systolic insufficiency or mitral stenosis complicated by pulmonary hypertension, the symptoms of left heart failure are often reduced due to reduced blood flow back to the left heart instead. The application of targeted drugs to reduce pulmonary artery pressure increases blood flow to the left heart, thereby aggravating the symptoms of left heart failure and leading to a poor prognosis, as has been demonstrated in trials; similarly, the application of targeted drugs to pulmonary hypoxic diseases, such as chronic obstructive pulmonary disease and interstitial pulmonary fibrosis, leads to vasodilation and increased blood flow in the local lung tissue areas that have lost oxygen exchange, thereby allowing more venous blood to flow back into the left heart system , aggravating hypoxia. At present, the patients suitable for targeted therapy are mainly the first major group of pulmonary hypertension, including: idiopathic pulmonary hypertension, heritable pulmonary hypertension, pulmonary hypertension caused by drugs or toxins, pulmonary hypertension associated with connective tissue disease, pulmonary hypertension associated with precordial disease, as well as HIV infection, portal hypertension, schistosomiasis and other causes. In addition, they are also effective in pediatric patients with persistent pulmonary hypertension and chronic thromboembolic pulmonary hypertension. Targeted therapeutic agents are of great value in patients with pulmonary hypertension associated with preexisting heart disease. In some patients with Eisenmenger’s syndrome even though it has already occurred, treatment over several months can lead to a significant decrease in pulmonary artery pressure and pulmonary vascular resistance, thus creating the opportunity for surgery and bringing the patient back from the dead. In patients with pulmonary hypertension associated with connective tissue disease, targeted drugs can reduce pulmonary pressure to full normal in some patients while intensifying treatment of the primary disease. There are three major classes of targeted drugs for pulmonary hypertension with proven efficacy: 1) 5-type phosphodiesterase inhibitors such as sildenafil, vardenafil, and tadalafil; 2) endothelin receptor antagonists such as aniracetam and bosentan; and 3) prostacyclin analogs such as iloprost, epoprostenol, travoprost, and beraprost. Prices vary widely between drugs, although there are no head-to-head comparisons, and efficacy is generally considered to vary. Type 5 phosphodiesterase inhibitors can be effective in the short term, but long-term treatment often requires dosing to achieve the same effect, thus increasing costs. On the premise of achieving the same effect, vardenafil is the cheapest, but currently many doctors and patients in China do not know much about the drug and instead apply sildenafil most widely; among the endothelin receptor antagonists, bosentan currently has an aid program from the China Charity Federation, so the cost is lower and the clinical evidence is most adequate, but the side effects of liver damage caused by andrisentan are much less. Among the prostacyclin analogs, beprostone is an oral drug that is inexpensive, but its efficacy is not definitive and can be used as an adjunct. Prostaglandin E1 (Prostaglandin E1) is an oral drug that is inexpensive and can be used as an adjunct. Prostaglandin E1 (Prostil) can dilate blood vessels and improve microcirculatory disorders, and can be used as adjuvant therapy for peripheral vascular disease, cardiovascular disease, heart failure, etc. It is not a target therapy drug for pulmonary hypertension, and its efficacy on pulmonary hypertension is not certain. Some doctors and patients confuse this drug with prostacyclin analogs. Fasudil (a meat kinase inhibitor) is a good option for patients with pulmonary hypertension who are hospitalized due to exacerbation and who can afford it financially. After two weeks of intravenous dosing, the majority of patients are able to stabilize their disease. In conclusion, there are many drugs available for patients with pulmonary hypertension, and they can be selected according to the patient’s specific situation. At present, only very few patients in China receive targeted drug therapy. Some patients do not receive treatment because of financial reasons, and another important reason is that they do not receive proper guidance from their doctors. In fact, unless the financial situation is particularly poor, most patients should be able to afford a certain level of treatment, such as vardenafil at a normal dose of about $1,000 per month, and bosentan at half dose of $2,000 per month. As long as it is taken, it will help to slow down the progression of the disease.